Fablyn
Fablyn is an experimental drug used for the treatment of osteoporosis. Developed by Pfizer and Ligand Pharmaceuticals, Fablyn has come under fire by the FDA. While the medication does prevent bone fractures in premenopausal women, it might also raise the risk of having life-threatening strokes, blood clots, and cancer.
Fast Facts
- Generic: lasofoxifene tartrate1
- Brand name: Fablyn1
- Developers: Pfizer and Ligand1
- 38% more deaths in group taking smallest dose of drug1
- Rejected by FDA in 20051
- Resubmitted December 20071
- FDA decision expected in October 20081
Related Pages on Mahalo
Pfizer | FDA | Boniva (Ibandronate) | Osteoporosis
Categories
